Pyxis Oncology, Inc. financial data

Symbol
PYXS on Nasdaq
Industry
Pharmaceutical Preparations
Location
321 Harrison Avenue, Boston, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 701 % -27.8%
Debt-to-equity 27.8 % +22.8%
Return On Equity -38.3 % +37.3%
Return On Assets -30 % +39.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 58.9M shares +49.1%
Common Stock, Shares, Outstanding 58.9M shares +49.6%
Entity Public Float 97M USD +26.1%
Common Stock, Value, Issued 59K USD +51.3%
Weighted Average Number of Shares Outstanding, Basic 60.5M shares +57.6%
Weighted Average Number of Shares Outstanding, Diluted 60.5M shares +57.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 16.1M USD
Cost of Revenue 475K USD
Research and Development Expense 53.3M USD -26.2%
General and Administrative Expense 31.2M USD -6.34%
Operating Income (Loss) -68.8M USD +34.8%
Nonoperating Income (Expense) 9.56M USD +46.5%
Net Income (Loss) Attributable to Parent -59.2M USD +40.2%
Earnings Per Share, Basic -1.25 USD/shares +56%
Earnings Per Share, Diluted -1.25 USD/shares +56%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 25.1M USD -3.18%
Marketable Securities, Current 131M USD +11.9%
Cash, Cash Equivalents, and Short-term Investments 156M USD +9.11%
Accounts Receivable, after Allowance for Credit Loss, Current 8M USD
Other Assets, Current 305K USD -19.9%
Assets, Current 161M USD +7.86%
Property, Plant and Equipment, Net 11.1M USD -12.5%
Operating Lease, Right-of-Use Asset 12.8M USD -5.05%
Intangible Assets, Net (Excluding Goodwill) 23.7M USD
Other Assets, Noncurrent 449K USD
Assets 208M USD +18.9%
Accounts Payable, Current 5.47M USD +319%
Employee-related Liabilities, Current 5.22M USD +23.1%
Accrued Liabilities, Current 10.1M USD +36.5%
Contract with Customer, Liability, Current 7.66M USD
Liabilities, Current 16.9M USD +83.2%
Deferred Income Tax Liabilities, Net 2.16M USD
Operating Lease, Liability, Noncurrent 19.4M USD -6.42%
Liabilities 38.6M USD +28.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -102K USD -20%
Retained Earnings (Accumulated Deficit) -307M USD -23.9%
Stockholders' Equity Attributable to Parent 170M USD +16.9%
Liabilities and Equity 208M USD +18.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -20.7M USD +22.8%
Net Cash Provided by (Used in) Financing Activities 57.5M USD
Net Cash Provided by (Used in) Investing Activities -18.5M USD +81.4%
Common Stock, Shares Authorized 190M shares 0%
Common Stock, Shares, Issued 58.9M shares +49.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 18.3M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 26.5M USD -3.01%
Deferred Tax Assets, Valuation Allowance 120M USD +107%
Deferred Tax Assets, Gross 127M USD +107%
Operating Lease, Liability 21.3M USD +12.7%
Payments to Acquire Property, Plant, and Equipment 237K USD -94.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -59.2M USD +40.2%
Lessee, Operating Lease, Liability, to be Paid 32.3M USD -7.05%
Property, Plant and Equipment, Gross 15.5M USD +19.1%
Operating Lease, Liability, Current 1.02M USD -15.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.28M USD +2.18%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.19M USD +24.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 10.9M USD -14.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.38M USD +2.21%
Deferred Tax Assets, Operating Loss Carryforwards 67.6M USD +415%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 2M USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.47M USD +2.18%
Operating Lease, Payments 1.1M USD +450%
Additional Paid in Capital 477M USD +21.3%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 1.12M USD +487%
Deferred Tax Assets, Net of Valuation Allowance 7.62M USD +107%
Share-based Payment Arrangement, Expense 15.6M USD -14.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%